Transient rise in CA 125 in a woman with ovarian carcinoma and COVID-19 infection

Smith, M.; Lara, Olivia D.; Pothuri, Bhavana

doi:10.1016/j.gore.2020.100644

Cited by 7 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case illustrates that in the presence of underlying malignancy and elevated CA125, COVID-19 infection may produce a dramatic increase in CA125 that resembles cancer progression. 11 Remarkably, the Hou et al 12 study is relevant to our study. They Therefore, early diagnosis and appropriate treatment are important in reducing the morbidity and mortality of COVID-19-infected patients.…”

Section: Discussionmentioning

confidence: 81%

“…The patient had a peak CA125 of 4499 U/ml, an increase of 2617 U/ml from the presumed pre‐COVID‐19 level, and only had mild infection not requiring hospitalization. This case illustrates that in the presence of underlying malignancy and elevated CA125, COVID‐19 infection may produce a dramatic increase in CA125 that resembles cancer progression 11 …”

Section: Discussionmentioning

confidence: 91%

“…Smith et al 11 have reported the case of a woman with FIGO stage IV A ovarian high‐grade serous carcinoma (HGSC) during the COVID‐19 pandemic, who had a transient increase in CA125 without evidence of progression of disease on imaging, and who was later found to have a positive COVID‐19 antibody test. The patient had a peak CA125 of 4499 U/ml, an increase of 2617 U/ml from the presumed pre‐COVID‐19 level, and only had mild infection not requiring hospitalization.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of the coronavirus pandemic on tumor markers

Purut

Giray

Gürbüz

2021

Journal of Medical Virology

View full text Add to dashboard Cite

The new type of coronavirus could cause severe acute respiratory syndrome and injuries in other systems as well. Multiple organ damage can occur rapidly in patients infected with coronavirus disease 2019 (COVID‐19). Previous studies have shown that many laboratory biomarkers were not within the normal ranges in COVID‐19 patients. We aimed to summarize laboratory parameters and the tumor markers in COVID‐19 patients. This is a retrospective cohort study conducted on 53 women between the ages of 19–85 years infected with COVID‐19 at a training and research hospital between May 2020 and August 2020. Of the 53 women, 16 (30.2%) had leukopenia. The mean C‐reactive protein level was 18.42 ± 59.33 mg/L. The mean procalcitonin level was 0.1 ± 0.21 µg/L. The liver function tests were within normal limits. The mean creatinine level was 0.58 ± 0.37 mg/dl. Elevated levels of α‐fetoprotein (AFP) in 1 patient, elevated levels of carcinoembryonic antigen (CEA) in 2 patients, elevated levels of cancer antigen 125 (CA125) in 4 patients, elevated levels of CA19‐9 in 2 patients, and elevated levels of CA15‐3 in 2 patients were detected. One of 4 patients who were taken to the intensive care unit had elevated levels of AFP. In addition, 2 of 4 patients who were taken to the intensive care unit had elevated levels of CA125 and CA15‐3. Except for AFP, levels of all tumor markers of the patient who died were high. We found that COVID‐19 had no effect on tumor markers (CA125, CA19‐9, CA15‐3, AFP, and CEA).

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of the coronavirus pandemic on tumor markers

Purut

Giray

Gürbüz

2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“… 15 Additionally, Smith et al reported a case of transient increase in CA 125 in a woman with ovarian serous carcinoma during the COVID‐19 pandemic. 32 While the patient was not tested with a PCR test at the time of infection, she later had a positive COVID‐19 antibody test, suggesting the rise in CA 125 may be related to the infection. 32 …”

Section: Discussionmentioning

confidence: 99%

“… 32 While the patient was not tested with a PCR test at the time of infection, she later had a positive COVID‐19 antibody test, suggesting the rise in CA 125 may be related to the infection. 32 …”

Section: Discussionmentioning

confidence: 99%

Tumor marker response to SARS‐CoV‐2 infection among patients with cancer

Gunn

Tashie²,

Wolf

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Inflammatory responses from benign conditions can cause non‐cancer‐related elevations in tumor markers. The severe acute respiratory coronavirus 2 (SARS‐CoV‐2) induces a distinct viral inflammatory response, resulting in coronavirus disease 2019 (COVID‐19). Clinical data suggest carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA 19–9), and cancer antigen 125 (CA 125) levels might rise in patients with COVID‐19. However, available data excludes cancer patients, so little is known about the effect of COVID‐19 on tumor markers among cancer patients. Methods We conducted a case series and identified patients with a positive SARS‐CoV‐2 PCR test, diagnosis of a solid tumor malignancy, and a CEA, CA 19–9, CA 125, or CA 27–29 laboratory test. Cancer patients with documented COVID‐19 infection and at least one pre‐ and two post‐infection tumor marker measurements were included. We abstracted the electronic health record for demographics, cancer diagnosis, treatment, evidence of cancer progression, date and severity of COVID‐19 infection, and tumor marker values. Results Seven patients were identified with a temporary elevation of tumor marker values during the post‐COVID‐19 period. Elevation in tumor marker occurred within 56 days of COVID‐19 infection for all patients. Tumor markers subsequently decreased at the second time point in the post‐infectious period among all patients. Conclusion We report temporary elevations of cancer tumor markers in the period surrounding COVID‐19 infection. To our knowledge this is the first report of this phenomenon in cancer patients and has implications for clinical management and future research.

show abstract

Carboplatin

2020

Reactions Weekly

View full text Add to dashboard Cite

Transient rise in CA 125 in a woman with ovarian carcinoma and COVID-19 infection

Cited by 7 publications

References 9 publications

Effect of the coronavirus pandemic on tumor markers

Effect of the coronavirus pandemic on tumor markers

Tumor marker response to SARS‐CoV‐2 infection among patients with cancer

Carboplatin

Contact Info

Product

Resources

About